These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 21925549)

  • 1. Proteomics in Parkinson's disease: An unbiased approach towards peripheral biomarkers and new therapies.
    Alberio T; Fasano M
    J Biotechnol; 2011 Dec; 156(4):325-37. PubMed ID: 21925549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in biomarkers for Parkinson's disease focusing on biochemicals, omics and neuroimaging.
    Ren R; Sun Y; Zhao X; Pu X
    Clin Chem Lab Med; 2015 Sep; 53(10):1495-506. PubMed ID: 25581757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-synuclein and Parkinson's disease: a proteomic view.
    Fasano M; Lopiano L
    Expert Rev Proteomics; 2008 Apr; 5(2):239-48. PubMed ID: 18466054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's and Parkinson's diseases: an environmental proteomic point of view.
    Demartini DR; Schilling LP; da Costa JC; Carlini CR
    J Proteomics; 2014 Jun; 104():24-36. PubMed ID: 24751585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of genomics and proteomics in understanding the role of modifying factors in Parkinson's disease.
    Singh MP; Patel S; Dikshit M; Gupta YK
    Indian J Biochem Biophys; 2006 Apr; 43(2):69-81. PubMed ID: 16955754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitochondrial proteomics as a selective tool for unraveling Parkinson's disease pathogenesis.
    Pienaar IS; Dexter DT; Burkhard PR
    Expert Rev Proteomics; 2010 Apr; 7(2):205-26. PubMed ID: 20377388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers in Parkinson's disease: Advances and strategies.
    Delenclos M; Jones DR; McLean PJ; Uitti RJ
    Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1(Suppl 1):S106-10. PubMed ID: 26439946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Network Analysis Identifies Disease-Specific Pathways for Parkinson's Disease.
    Monti C; Colugnat I; Lopiano L; Chiò A; Alberio T
    Mol Neurobiol; 2018 Jan; 55(1):370-381. PubMed ID: 28004338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs.
    Mandel S; Weinreb O; Youdim MB
    Drug Discov Today; 2004 Dec; 9(24 Suppl):S37-44. PubMed ID: 23573659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs.
    Mandel S; Weinreb O; Youdim MB
    Trends Pharmacol Sci; 2003 Apr; 24(4):184-91. PubMed ID: 12707005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarker discovery in neurodegenerative diseases: a proteomic approach.
    Shi M; Caudle WM; Zhang J
    Neurobiol Dis; 2009 Aug; 35(2):157-64. PubMed ID: 18938247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of animal models of Parkinson's disease for neuroprotective strategies.
    Emborg ME
    J Neurosci Methods; 2004 Oct; 139(2):121-43. PubMed ID: 15488225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can Biomarkers Help the Early Diagnosis of Parkinson's Disease?
    Le W; Dong J; Li S; Korczyn AD
    Neurosci Bull; 2017 Oct; 33(5):535-542. PubMed ID: 28866850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C. elegans as a model organism to investigate molecular pathways involved with Parkinson's disease.
    Harrington AJ; Hamamichi S; Caldwell GA; Caldwell KA
    Dev Dyn; 2010 May; 239(5):1282-95. PubMed ID: 20108318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A critical appraisal of the premotor symptoms of Parkinson's disease: potential usefulness in early diagnosis and design of neuroprotective trials.
    Lang AE
    Mov Disord; 2011 Apr; 26(5):775-83. PubMed ID: 21484865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in Parkinson's disease-where do we stand?
    Toulouse A; Sullivan AM
    Prog Neurobiol; 2008 Aug; 85(4):376-92. PubMed ID: 18582530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding Epigenetic Alterations in Alzheimer's and Parkinson's Disease: Towards Targeted Biomarkers and Therapies.
    Ciceri F; Rotllant D; Maes T
    Curr Pharm Des; 2017; 23(5):839-857. PubMed ID: 28120717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers in Parkinson's disease (recent update).
    Sharma S; Moon CS; Khogali A; Haidous A; Chabenne A; Ojo C; Jelebinkov M; Kurdi Y; Ebadi M
    Neurochem Int; 2013 Sep; 63(3):201-29. PubMed ID: 23791710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using 'omics' to define pathogenesis and biomarkers of Parkinson's disease.
    Caudle WM; Bammler TK; Lin Y; Pan S; Zhang J
    Expert Rev Neurother; 2010 Jun; 10(6):925-42. PubMed ID: 20518609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomics in Parkinson's disease: current trends, translational snags and future possibilities.
    Srivastava G; Singh K; Tiwari MN; Singh MP
    Expert Rev Proteomics; 2010 Feb; 7(1):127-39. PubMed ID: 20121482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.